All true ... between the insiders, Eversana, Hepa, Ori, Dart, BP's, Hedge Funds, Sheikh's in the middle east, personal funds, and maybe "shark tank" lol ... they just need to get these very promising studies moving toward ROI for all involved. 

Even given numerous shortfalls, this is still very promising technology with a relatively short journey ahead potentially to NDA and ROI, at this point. With huge under-served markets waiting for therapeutic answers. An argument could be made that the previous shortfalls have served to refine the critical success factors and targets, and they appear very achievable. 

Mind boggling at times that this has stayed on the slow track. I remember Don saying not that long ago that there was no shortage of interest or money. Uh huh. So show me the money, big mouth, instead of a broken financial pillar on a ppt presentation, and let's roll. 

And I'm still continually tempted to buy more, especially at this ridiculous PPS for RVX stock given where the science sits right now. 

Can the science and market need overcome the weak management?!